Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Correction of a release from 21.11.2016, 18:05 CET - MorphoSys AG: Publication pursuant to §26 sect.1 WpHG (the German Securities Trading Act) with the aim of pan-European distribution

MorphoSys AG
Posted on: 22 Nov 16
X Notification of Major Holdings  

or

  Correction of a notification of Major Holding published on   (date of publication)

1. Details of issuer (name, address)

MorphoSys AG

Lena-Christ-Str. 48

82152 Martinsried/Planegg, Germany

2. Reason for notification (multiple reasons possible)

 Acquisition/disposal of shares with voting rights

 Acquisition/disposal of instruments

 Change of breakdown of voting rights

X Other reason: Voluntary Group Disclosure due to Issuer increasing the number of voting rights

3. Details of person subject to the notification obligation

Name:

Baillie Gifford & Co
City and country of registered office (if applicable):

Edinburgh, Scotland
  

4. Names of shareholder(s) holding directly 3% or more voting rights, if different from 3.

 

5. Date on which threshold was crossed or reached: 17.11.2016

6. Total positions
 % of voting rights attached to shares (total of 7.a.) % of voting rights through instruments
(total of 7.b.1 + 7.b.2)
total of both in % (7.a. + 7.b.)total number of voting rights of issuer
Resulting situation5.41%0%5.41%29159770
Previous notification (if applicable)5.90%0%5.90% 


7. Notified details of the resulting situation
a. Voting rights attached to shares (Sec. 21, 22 WpHG)
ISINabsolutein %
direct

(Sec. 21 WpHG)
indirect

(Sec. 22 WpHG)
direct

(Sec. 21 WpHG)
indirect

(Sec. 22 WpHG)
DE0006632003  1577507 %5.41%
     % %
Total 1577507 5.41%

b.1. Instruments according to Sec. 25 Abs. 1 Nr. 1 WpHG (please use annex in case of more than 3 instruments)
Type of instrumentExpiration or maturity dateExercise or conversion periodVoting rights absoluteVoting rights in %
          %
          %
          %
    Total     %

b.2 Instruments according to Sec. 25 Abs. 1 Nr. 2 WpHG (please use annex in case of more than 3 instruments)
Type of instrumentExpiration or maturity dateExercise or conversion periodCash or physical settlementVoting rights absoluteVoting rights in %
            %
            %
            %
      Total     %

8. Information in relation to the person subject to the notification obligation (please tick the applicable box) :

 

[ ] Person subject to the notification obligation is not controlled and does itself not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer (1.).

 

[X] Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity (please use annex in case of more than 4 undertakings; in this case please always provide only to BaFin also an organizational chart accompanying your notification):

 
Name % of voting rights
(if at least held 3% or more)
% of voting rights through instruments
(if at least held 5% or more)
Total of both
(if at least held 5% or more)
Baillie Gifford & Co % % %
Baillie Gifford Overseas Limited4.71% % 
  % % %
  % % %

9. In case of proxy voting according to § 22 Abs. 3 WpHG

Date of general meeting:  

Holding position after general meeting:   % (equals   voting rights)


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: MorphoSys AG via GlobeNewswire
HUG#2058610
GlobeNewswire
globenewswire.com

Last updated on: 23/11/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.